These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 34080754)

  • 1. Multidisciplinary Care of BRAF-Mutant Stage III Melanoma: A Physicians Perspective Review.
    Cornelius LA; Fields RC; Tarhini A
    Oncologist; 2021 Sep; 26(9):e1644-e1651. PubMed ID: 34080754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF
    Schadendorf D; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Lesimple T; Plummer R; Schachter J; Dasgupta K; Manson S; Koruth R; Mookerjee B; Kefford R; Dummer R; Kirkwood JM; Long GV
    Lancet Oncol; 2019 May; 20(5):701-710. PubMed ID: 30928620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting.
    Scolyer RA; Atkinson V; Gyorki DE; Lambie D; O'Toole S; Saw RPM; Amanuel B; Angel CM; Button-Sloan AE; Carlino MS; Ch'ng S; Colebatch AJ; Daneshvar D; Pires da Silva I; Dawson T; Ferguson PM; Foster-Smith E; Fox SB; Gill AJ; Gupta R; Henderson MA; Hong AM; Howle JR; Jackett LA; James C; Lee CS; Lochhead A; Loh D; McArthur GA; McLean CA; Menzies AM; Nieweg OE; O'Brien BH; Pennington TE; Potter AJ; Prakash S; Rawson RV; Read RL; Rtshiladze MA; Shannon KF; Smithers BM; Spillane AJ; Stretch JR; Thompson JF; Tucker P; Varey AHR; Vilain RE; Wood BA; Long GV
    Pathology; 2022 Feb; 54(1):6-19. PubMed ID: 34937664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation.
    Kiniwa Y; Nakamura K; Mikoshiba A; Ashida A; Akiyama Y; Morimoto A; Okuyama R
    BMC Cancer; 2021 Mar; 21(1):287. PubMed ID: 33731038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognosis and Management of BRAF V600E-Mutated Pregnancy-Associated Melanoma.
    Ziogas DC; Diamantopoulos P; Benopoulou O; Anastasopoulou A; Bafaloukos D; Stratigos AJ; Kirkwood JM; Gogas H
    Oncologist; 2020 Aug; 25(8):e1209-e1220. PubMed ID: 32271498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological features and clinical outcomes associated with TP53 and BRAF
    Kim DW; Haydu LE; Joon AY; Bassett RL; Siroy AE; Tetzlaff MT; Routbort MJ; Amaria RN; Wargo JA; McQuade JL; Kemnade J; Hwu P; Woodman SE; Roszik J; Kim KB; Gershenwald JE; Lazar AJ; Davies MA
    Cancer; 2017 Apr; 123(8):1372-1381. PubMed ID: 27911979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SEOM clinical guideline for the management of cutaneous melanoma (2020).
    Majem M; Manzano JL; Marquez-Rodas I; Mujika K; Muñoz-Couselo E; Pérez-Ruiz E; de la Cruz-Merino L; Espinosa E; Gonzalez-Cao M; Berrocal A
    Clin Transl Oncol; 2021 May; 23(5):948-960. PubMed ID: 33651321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy.
    Barbour AP; Tang YH; Armour N; Dutton-Regester K; Krause L; Loffler KA; Lambie D; Burmeister B; Thomas J; Smithers BM; Hayward NK
    Eur J Cancer; 2014 Oct; 50(15):2668-76. PubMed ID: 25070294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Navigating Diagnostic and Treatment Decisions in Non-Small Cell Lung Cancer: Expert Commentary on the Multidisciplinary Team Approach.
    Popat S; Navani N; Kerr KM; Smit EF; Batchelor TJP; Van Schil P; Senan S; McDonald F
    Oncologist; 2021 Feb; 26(2):e306-e315. PubMed ID: 33145902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAF-Mutated Melanoma Journey in Latin America: Expert Recommendations From Diagnosis to Treatment.
    Bravo-Garzón MA; Bornstein-Quevedo L; Camargo VP; Sanku G; Jansen AM; Macedo MP; Rico-Restrepo M; Chacón M
    Cancer Control; 2024; 31():10732748241251572. PubMed ID: 38751033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and prognostic significance of BRAF V600E mutation in non-metastatic cutaneous melanoma patients.
    Tas F; Erturk K
    Neoplasma; 2019 Jul; 66(4):631-636. PubMed ID: 31058533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma proteome alterations by MAPK inhibitors in BRAF
    Babačić H; Eriksson H; Pernemalm M
    Neoplasia; 2021 Aug; 23(8):783-791. PubMed ID: 34246984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frontline approach to metastatic BRAF-mutant melanoma diagnosis, molecular evaluation, and treatment choice.
    Chapman PB; Hauschild A; Sondak VK
    Am Soc Clin Oncol Educ Book; 2014; ():e412-21. PubMed ID: 24857132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of BRAF V600E mutational status in capsular nevi of sentinel lymph nodes in patients with primary cutaneous melanoma.
    Siroy AE; Aung PP; Torres-Cabala CA; Tetzlaff MT; Nagarajan P; Milton DR; Curry JL; Ivan D; Prieto VG
    Hum Pathol; 2017 Jan; 59():48-54. PubMed ID: 27666765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive Review on the Clinical Relevance of Long Non-Coding RNAs in Cutaneous Melanoma.
    De Falco V; Napolitano S; Esposito D; Guerrera LP; Ciardiello D; Formisano L; Troiani T
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33503876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association between dermoscopic features and BRAF mutational status in cutaneous melanoma: Significance of the blue-white veil.
    Armengot-Carbó M; Nagore E; García-Casado Z; Botella-Estrada R
    J Am Acad Dermatol; 2018 May; 78(5):920-926.e4. PubMed ID: 29307636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF V600 mutations and pathological features in Japanese melanoma patients.
    Yamazaki N; Tanaka R; Tsutsumida A; Namikawa K; Eguchi H; Omata W; Oashi K; Ogawa T; Hayashi A; Nakamura N; Tsuta K
    Melanoma Res; 2015 Feb; 25(1):9-14. PubMed ID: 25051202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Principles of Targeted Therapy for Melanoma.
    Sun J; Carr MJ; Khushalani NI
    Surg Clin North Am; 2020 Feb; 100(1):175-188. PubMed ID: 31753111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care.
    Heppt MV; Siepmann T; Engel J; Schubert-Fritschle G; Eckel R; Mirlach L; Kirchner T; Jung A; Gesierich A; Ruzicka T; Flaig MJ; Berking C
    BMC Cancer; 2017 Aug; 17(1):536. PubMed ID: 28797232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of BRAF(V⁶⁰⁰) mutations in melanoma patients after resection of metastatic lymph nodes.
    Moreau S; Saiag P; Aegerter P; Bosset D; Longvert C; Hélias-Rodzewicz Z; Marin C; Peschaud F; Chagnon S; Zimmermann U; Clerici T; Emile JF
    Ann Surg Oncol; 2012 Dec; 19(13):4314-21. PubMed ID: 22772867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.